21:46 , Jun 25, 2019 |  BC Extra  |  Company News

Gilead to add lipid kinase inhibitors to pipeline via Carna deal

Gilead has partnered with Carna to develop small molecule inhibitors of lipid kinases in the bellwether’s second deal to bolster its cancer portfolio since CEO Daniel O’Day arrived. Gilead Sciences Inc. (NASDAQ:GILD) will pay Carna...
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; inflammation

INDICATION: Rheumatoid arthritis (RA); allergy In vitro , mouse, rat and dog studies identified an aminotriazine-based Btk inhibitor that could help treat RA and allergy. Chemical synthesis, in vitro testing in activity assays and optimization...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: TRAF2 and NCK interacting kinase (TNIK)

Cancer INDICATION: Colorectal cancer Cell culture and mouse studies suggest inhibiting TNIK could help treat colorectal cancer. In a human colorectal carcinoma cell line, the TNIK inhibitor NCB-0846 decreased tumor cell colony formation compared with...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Carna, J&J deal

Carna granted Johnson & Johnson’s Janssen Biotech unit exclusive, worldwide rights to develop and commercialize small molecule protein kinase inhibitors for autoimmune and inflammatory diseases. Carna will receive an upfront payment and is eligible for...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
07:00 , Jun 17, 2013 |  BioCentury  |  Finance

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Company News

Carna, RaQualia deal

RaQualia and Carna partnered to discover a compound targeting an undisclosed kinase. Carna will contribute its kinase drug discovery technologies, and RaQualia will contribute its screening capabilities. The partners will equally share rights to a...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Out fast at opening bell

For the second year in a row, biotech put together a strong showing in the first quarter with all market segments gaining ground. The sector was led by mid-caps, which closed up 16%. Large caps...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) gained DKK4 to DKK420.50 last week after it and partner Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review a BLA from Merck for grass Allergy Immunotherapy Tablet (AIT)....
00:34 , Mar 27, 2013 |  BC Extra  |  Company News

RaQualia, Carna in discovery deal

RaQualia Pharma Inc. (JASDAQ:4579) and Carna Biosciences Inc. (JASDAQ:4572) partnered to discover a compound for an undisclosed kinase. Carna will contribute its kinase drug discovery technologies, and RaQualia will contribute its screening capabilities. The partners...